Publication:
İdiyopatik Parkinson Hastalığında Serüloplazminin Nörodejenerasyonda Rolü

Simple item page
dc.contributor.authorAyaz, Tunahan
dc.contributor.authorGürer, Reyhan
dc.contributor.authorGökçe, Dilvin
dc.contributor.authorIşık, Nihal
dc.contributor.authorAydın, Şenay
dc.contributor.institutionİstanbul Medeniyet Üniversitesi
dc.contributor.institutionT.C. Sağlık Bakanlığı
dc.contributor.institutionT.C. Sağlık Bakanlığı
dc.contributor.institutionBahçeşehir Üniversitesi
dc.contributor.institutionT.C. Sağlık Bakanlığı
dc.date.accessioned2025-09-20T20:02:23Z
dc.date.issued2016
dc.date.submitted29.07.2022
dc.description.abstractAmaç: İdiyopatik Parkinson hastalığında (İPH) oksidatif stres nöronal hücre ölümü üzerinde majör role sahiptir. Serüloplazmin ferrooksidaz aktivitesi ile ferröz demiri ferrik forma okside eder ve böylece hücrenin DNA, lipid ve protein bileşenlerini oksidatif hasardan korur. Bizim çalışmamızda proton manyetik rezonans spektroskopi (H-1 MRS) ile serüloplazmin eksikliğinin nörodejenerasyon üzerindeki etkisi araştırılmıştır.Gereç ve Yöntem: İPH tanılı 23 hasta ve 12 sağlıklı kontrol olguda iki yanlı putamen tek voksel H-1 MRS yöntemiyle incelendi. Her iki grupta N-asetil aspartat (NAA), kreatin (Cr) ve kolin (Cho) pik değerleri ve serum serüloplazmin düzeyleri belirlendi. Bulgular: İPH hastalarında semptomatik ekstremitenin kontralateral (KL) putaminal bölge NAA/Cho ve NAA/Cr oranı kontrol grubuna kıyasla anlamlı derecede düşüktü. Ayrıca İPH grubunda KL NAA/Cho ve NAA/Cr oranları ipsilateraline (İL) göre anlamlı derecede düşüktü (p<0,001). Semptomatik ekstremitenin İL putaminal bölgeye ait metabolit oranları karşılaştırıldığında sağlıklı kontrol ile İPH grubu arasında anlamlı fark saptanmadı. Serum serüloplazmin seviyeleri kontrol grubu ile karşılaştırıldığında İPH grubunda anlamlı derecede düşük saptandı (p<0,001). İPH grubunda KL putaminal NAA/Cho oranı ile serüloplazmin seviyeleri arasında anlamlı korelasyon saptandı (p=0,011).Sonuç: Çalışmamızda saptanan serum serüloplazmin düşüklüğü ile KL putamen NAA/Cho oranı arasındaki bu korelasyon serbest radikal aracılı nöronal hücre ölümünde serüloplazmin yetersizliğinin katkıda bulunabileceği hipotezini desteklemektedir.
dc.identifier.endpage25
dc.identifier.issn1301-062X
dc.identifier.issn1309-2545
dc.identifier.issue1
dc.identifier.startpage19
dc.identifier.urihttps://hdl.handle.net/20.500.14719/5652
dc.identifier.volume22
dc.language.isotr
dc.relation.journalTürk Nöroloji Dergisi
dc.subjectPatoloji
dc.subjectKlinik Nöroloji
dc.subjectNörolojik Bilimler
dc.titleİdiyopatik Parkinson Hastalığında Serüloplazminin Nörodejenerasyonda Rolü
dc.typeResearch Article
dcterms.references1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003,302:819-822.,2. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II J Neuropathol Exp Neurol 2007,66:329-336.,3. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995,38:357-366.,4. Halliwell B. Oxygen radicals as key mediators in neurological disease: Fact or fiction? Ann Neurol 1992,32:10-15.,5. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994,344:796-798.,6. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999,122:1437-1448.,7. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003,24:197-211.,8. Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000,123:2423-2431.,9. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004,5:863-873.,10. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. JAlzheimer's Dis 2009,16:879-895.,11. Barnham KJ, Masters CL, Torsdottir G, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004,3:205-214.,12. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991,114:1953-1975.,13. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 2006,21:1299-1310.,14. Rhodes SL, Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 2008,32:183-195.,15. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, Lewitt PA. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995,65:710-724.,16. Bharucha KJ, Friedman JK, Vincent AS, Ross ED. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 2008,255:1957-1962.,17. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002,29:433-238.,18. Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages. Acad Radiol 2014,21:64-71.,19. Kristinsson J, Snaedal J, Tórsdóttir G, Jóhannesson T. Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: A synopsis of recent studies. Neuropsychiatr Dis Treat 2012,8:515-521.,20. Graf WD, Noetzel M. J. Radical reactions from missing ceruloplasmin, the importance of a ferroxidase as an endogenous antioxidant. Neurology 1999,53:446-447.,21. Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). J Biol Chem 1966,241:5053-5059.,22. Lee GR, Nacht S, Leukens JN, Cartwright GE. Iron metabolism in copperdeficient swine. J Clin Invest 1968,47:2058-2069.,23. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005,49:633-640.,24. Texel SJ, Xu X, Harris ZL. Ceruloplasmin in neurodegenerative diases. Biochem Soc Trans 2008,36:1277-1281.,25. Okamoto N, Wada S, Oga T, Kawabata Y, Baba Y, Habu D, Takeda Z, Wada Y. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum Genet 1996,97:755-758.,26. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995,92:2539-2543.,27. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, Kato M, Yanagisawa N. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family. Ann Neurol 1995,37:646-656.,28. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates ıron levels in the CNS and prevents free radical injury. The Journal of Neuroscience 2002,22:6578-6586.,29. Warren KE. NMR spectroscopy and pediatric brain tumors. Oncologist 2004,9:312-318.,30. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999,56:33-39.,31. Akbostancı MC, Balaban H, Atbaşoğlu C. Birleşik Parkinson Hastalığı Değerleme Ölçeği Motor Muayene Bölümü ve Anormal İstemsiz Hareketler Ölçeği'nin değerlendiriciler arası güvenilirlik çalışması. Parkinson Hastalığı ve Hareket Bozukluğu Dergisi 2000,3:7-13.,32. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression, and mortality. Neurology 1967,17:427-442.,33. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in parkinson's disease. Neurology 2004,63:1912-1917.,34. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Krüger R, Becker G, Riess O, Berg D. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J 2005,19:1851-1853.,35. Lirong J, Jianjun J, Hua Z, Guoqiang F, Yuhao Z, Xiaoli P, Xiaomin Z, Yuwen Z, Yu M, Jie C, Jihong D, Yueshi M, Zhenyao M, Chunjiu Z. Hypoceruloplasminemia-related movement disorder without KayserFleischer rings is different from Wilson disease and not involved in ATP7B mutation. Eur J Neurol 2009,16:1130-1137.,36. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011,134:50-58.,37. Jin L, Wang J, Jin H, Fei G, Zhang Y, Chen W, Zhao L, Zhao N, Sun X, Zeng M, Zhong C. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur J Neurol 2012,19:969-976.,38. Hornykiewice O. Biochemical aspects of Parkinson's disease. Neurology 1998,51(Suppl 2):2-9.,39. Burlina AP, Aureli T, Bracco F, Conti F, Battistin L. MR spectroscopy: A powerful tool for investigating brain function and neurological diseases. Neurochemical Research 2000,25:1365-1372.,40. Lenz FA, Normand SL, Kwan HC, Andrews D, Rowland LH, Jones MW, Seike M, Lin YC, Tasker RR, Dostrovsky JO. Statistical prediction of the optimal site for thalamotomy in parkinsonian tremor. Mov Disord 1995,10:318-328.,41. Birken DL, Oldendorf WH. N-acetyl-aspartate acid: A literature review of a compound prominent in 1H NMR spectroscopic studies of the brain. Neurosci Rev 1989,13:23-31.,42. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hänicke W, Sauter R, Hamburger C. Noninvasive differentiation of tumors with use of localized 1H MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989,172:541-548.,43. Langkowski JH, Wieland J, Bomsdorf H, Leibfritz D, Westphal M, Offermann W, Maas R. Pre-operative localized in-vivo proton spectroscopy in cerebral tumors at 4.0 Tesla-first results. Magn Reson Imaging 1989,7:547-555.,44. Gill SS, Thomas DG, Van Bruggen N, Gadian DG, Peden CJ, Bell JD, Cox IJ, Menon DK, Iles RA, Bryant DJ. Proton MR spectroscopy of intracranial tumors: in-vivo and in-vitro studies. J Comput Assist Tomogr 1990,14:497- 504.,45. Gill SS, Small RK, Thomas DG, Patel P, Porteous R, Van Bruggen N, Gadian DG, Kauppinen RA, Williams SR. Brain metabolites as 1H NMR markers of neuronal and glial disorders. NMR Biomed 1989,2:196-200.,46. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984,43:1136-1142.,47. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med 1989,9:126-131.,48. Algin O, Taskapilioglu O, Hakyemez B, Ocakoglu G, Yurtogullari Ş, Erer S, Parlak M. Structural and neurochemical evaluation of the brain and pons in patients with Wilson's disease. Jpn J Radiol 2010,28:663-671.,49. Menon DK, Bau douin CJ, Tomlinson D, Hoyle C. Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comput Assist Tomogr 1990,14:882-885.,50. Van Hecke P, Marchal G, Johannik K, Demaerel P, Wilms G, Carton H, Baert AL. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med 1991,18:199-206.,51. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991,41:1251-1256.,52. Chang KH, Kim HD, Park SW, Song IC, Yu IK, Han MH, Lee SK, Chung CK, Park YH. Usefulness of single voxel proton MR spectroscopy in the evaluation of hippocampal sclerosis. Korean J Radiol 2000,1:25-32.,53. Lu D, Pavlakis SG, Frank Y, Bakshi S, Pahwa S, Gould RJ, Sison C, Hsu C, Lesser M, Hoberman M, Barnett T, Hyman RA. Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Radiology 1996,199:423-428.,54. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 1995,195:65-72.,55. Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn N, McDonald WI, Marsden CD, Miller DH. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995,37:204-210.,56. Holshouser BA, Komu M, Möller HE, Zijlmans J, Kolem H, Hinshaw DB Jr, Sonninen P, Vermathen P, Heerschap A, Masur H. Localized proton NMR spectroscopy in the striatum of patients with Parkinson's disease: A multicentre pilot study. Magn Reson Med 1995,33:589-594.,57. Choe BY, Park JW, Lee KS, Son BC, Kim MC, Kim BS, Suh TS, Lee HK, Shinn KS. Neuronal laterality in Parkinson's disease with unilateral symptom by in-vivo 1H MR spectroscopy. Invest Radiol 1998,33:450-455.,58. Ellis CM, Lemmens G, Williams SC, Simmons A, Dawson J, Leigh PN, Chaudhuri KR. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopatreated Parkinson's disease: A proton magnetic resonance spectroscopy study. Neurology 1997,49:438-444.,59. Clarke CE, Lowry M, Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov disord 1997,12:297-301.,60. Chaudhuri KR, Lemmens GM, Williams SC, Ellis C, Lloyd CM, Dawson J, Simmons A, Leigh PN. Proton magnetic resonance of the striatum in Parkinson's disease patients with motor response fluctuations. Parkinsonism Relat Disord 1996,2:63-67.,61. Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease. J Neuroimaging 2015,25:105-110.,62. Gallagher DA, Schapira AH. Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem 2009,9:860-868.,63. Zhou B, Yuan F, He Z, Tan C. Application of proton magnetic resonance spectroscopy on substantia nigra mebolites in Parkinson's disease. Brain Imaging Behav 2014,8:97-101.,64. Abe K, Terakawa H, Takanashi M, Watanabe Y, Tanaka H, Fujita N, Hirabuki N, Yanagihara T. Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull 2000,52:589-595.,65. Watanabe H, Fukatsu H, Katsuno M, Sugiura M, Hamada K, Okada Y, Hirayama M, Ishigaki T, Sobue G. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry. 2004,75:103-109.
dspace.entity.typePublication
local.indexed.atTRDizin

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
İdiyopatik Parkinson Hastalığında Serüloplazminin Nörodejenerasyonda Rolü.pdf
Size:
187.18 KB
Format:
Adobe Portable Document Format
Download

Collections

TR-Dizin İndeksli Yayınlar Koleksiyonu